T790M drug resistance mutation.[6–8] WJTOG3405 clinical study confirmed the predictive effect of EGFR mutation on the efficacy of tyrosine kinase inhibitor (TKI) (Tyrosine Kinase Inhibitors, tyrosine kinase inhibitor) drugs in the treatment of non-small cell lung cancer non-small cell lung cancer (NSCLC).[9] Detection of the mutation status of related genes has become a predictor of the clinical efficacy of targeted drugs in non-small cell lung cancer and other tumor types.[10]. Here, EGFR is linked to non-small cell lung carcinoma.